Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent cisplatin and intensitymodulated pelvic radiotherapy: Comparison with conventional radiotherapy
Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent cisplatin and intensitymodulated pelvic radiotherapy: Comparison with conventional radiotherapy
复制标题
DOI：
10.1016/j.ijrobp.2006.11.005
复制
发表时间：
2007-04-01
影响因子：
7
通讯作者：
Chen, Wen-Cheng
中科院分区：
文献类型：
--
作者：
Chen, Miao-Fen;Tseng, Chih-Jen;Chen, Wen-Cheng
目的：评估调强放射治疗（IMRT）作为宫颈癌辅助治疗的局部控制和急、慢性毒性。方法和材料：2002年4月至2006年2月期间，68例子宫切除术后宫颈癌高危患者接受了辅助盆腔放疗和同步化疗。辅助化疗包括顺铂（50 mg/m2），每周6个周期。33例患者接受IMRT辅助放疗。在IMRT系列开始之前，其他35例患者接受常规四野放疗（Box-RT）。两组在临床病理和治疗factors.Results方面没有显着差异：IMRT提供兼容的局部肿瘤控制与Box-RT. Accurate 1年locoregional控制的IMRT和Box-RT组的患者分别为93%和94%。IMRT耐受性良好，与Box-RT组相比，急性胃肠道（GI）和泌尿生殖系统（GU）毒性显著降低（GI 36 vs. 80%，p = 0.00012; GU 30 vs. 60%，p = 0.022）。此外，IMRT组的慢性GI和GU毒性发生率低于Box-RT组（GI 6 vs. 34%，p = 0.002; GU 9 vs. 23%，p = 0.231）。我们的研究结果表明，与常规Box-RT相比，IMRT显著提高了对辅助放化疗的耐受性，需要更长的随访时间和更多的患者来证实IMRT的益处。(c)2007爱思唯尔公司
Purpose: To assess local control and acute and chronic toxicity with intensity-modulated radiation therapy (IMRT) as adjuvant treatment of cervical cancer.Methods and Materials: Between April 2002 and February 2006, 68 patients at high risk of cervical cancer after hysterectomy were treated with adjuvant pelvic radiotherapy and concurrent chemotherapy. Adjuvant chemotherapy consisted of cisplatin (50 mg/m(2)) for six cycles every week. Thirty-three patients received adjuvant radiotherapy by IMRT. Before the IMRT series was initiated., 35 other patients underwent conventional four-field radiotherapy (Box-RT). The two groups did not differ significantly in respect of clinicopathologic and treatment factors.Results: IMRT provided compatible local tumor control compared with Box-RT. The actuarial 1-year locoregional control for patients in the IMRT and Box-RT groups was 93% and 94%, respectively. IMRT was well tolerated, with significant reduction in acute gastrointestinal (GI) and genitourinary (GU) toxicities compared with the Box-RT group (GI 36 vs. 80%, p = 0.00012; GU 30 vs. 60%, p = 0.022). Furthermore, the IMRT group had lower rates of chronic GI and GU toxicities than the Box-RT patients (GI 6 vs. 34%, p = 0.002; GU 9 vs. 23%, p = 0.231).Conclusion: Our results suggest that IMRT significantly improved the tolerance to adjuvant chemoradiotherapy with compatible locoregional control compared with conventional Box-RT. However, longer follow-up and more patients are needed to confirm the benefits of IMRT. (c) 2007 Elsevier Inc.